Login
$OPRX
$6.76 +$0.12 (1.81%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Joined 2025 pay Source
Stephen L. Silvestro Also a director
Chief Executive Officer
48 Since 2025
1 year
2019 $2,717,717
Brendan Merrell
Chief Operating Officer
41 Since 2025
1 year
2020 Not reported
Edward Stelmakh
Chief Finance & Strat Officer
Title from the Form 4 dated Aug 21, 2026
60 Not stated 2021 $1,524,170
Doug Besch
Chief Product & Technology Officer
44 Since 2025
1 year
2021 Not reported
Andrew D’Silva
Chief Business Officer
40 Since 2025
1 year
2021 Not reported
Marion Odence-Ford
Chief Legal & Admin Officer
Title from the Form 4 dated Aug 21, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
5.3 years
from year joined
CEO also chairs the board
No
Lynn O’Connor Vos
Director Age On board Independent 2025 pay Source
Lynn O’Connor Vos
70 2015
11 years
Independent $268,994
Stephen Silvestro
48 2025
1 year
Not independent Paid as CEO
Catherine Klema
67 2024
2 years
Independent $227,994
James Lang
61 2017
9 years
Independent $203,994
Patrick Spangler
70 2018
8 years
Independent $234,994
Mariyamma Varghese Presti
52 2026
this year
Independent Not stated
Gregory Wasson
67 2020
6 years
Independent $200,994

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 30, 2026
James Lang
one of our Board Members; formerly Chief Executive Officer of Eversana Life Science Services, LLC and now serves on EVERSANA's Board of Directors
$922,416 and $375,280
2025 and 2024

Reseller Agreement under which EVERSANA may offer OptimizeRx solutions to its life sciences customers, generating revenue for OptimizeRx

With EVERSANA Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support